Pharmstandard PJSC

Pharmstandard PJSC

Pharmstandard PJSC

Overview
Date Founded

2002

Headquarters

5B, Likhachevsky Drive,North Tower Business Centre,1 entrance, 10 Testovskaya,Dologoprudny, Moscow 141700

Type of Company

Private

Employees (Worldwide)

6,655

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries

Company Description

Pharmstandard PJSC engages in the production and wholesale distribution of pharmaceutical and medical products. It operates through the following segments: Production and Wholesale of Pharmaceutical Products, and Production and Wholesale of Medical Equipment. The company was founded on March 23, 2003 and is headquartered in Dologoprudny, Russia.

Contact Data
Trying to get in touch with decision makers at Pharmstandard PJSC? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Deputy Chief Executive Officer, New Products Development

Deputy Chief Executive Officer for Legal Affairs

Deputy Chief Executive Officer for Intellectual Property

Executive Director

Executive Director

Executive Director

Executive Director

Executive Director

Chief Operating Officer

Board of Directors

Executive Director at Pharmstandard PJSC

Chief Executive Officer at Pharmstandard PJSC

Deputy Chief Executive Officer, New Products Development at Pharmstandard PJSC

Deputy Chief Executive Officer for Legal Affairs at Pharmstandard PJSC

Chief Operating Officer at Pharmstandard PJSC

Paths to Pharmstandard PJSC
Potential Connections via
Relationship Science
You
Pharmstandard PJSC
Recent Transactions
Details Hidden

Pharmstandard PJSC, Augment Investments Ltd. purchase PET-Technology OOO from Rusnano, Essedel Capital Partners Oy

Details Hidden

Pharmstandard PJSC, Augment Investments Ltd. purchase PET-Technology OOO from D-Med LLC

Details Hidden

Augment Investments Ltd. purchases Pharmstandard PJSC

Transaction Advisors
Investment Advisor

Advised on purchases OTCPharm PJSC from Pharmstandard PJSC

Investment Advisor

Advised onAugment Investments Ltd. purchases Pharmstandard PJSC

Legal Advisor

Advised onPharmstandard PJSC purchases Bever Pharmaceutical Pte Ltd. from Bristley Enterprises Ltd.

Associate

Advised onMillhouse Capital Doo, Pharmstandard PJSC purchase Biocad Holding Ltd.

Counsel

Advised onMillhouse Capital Doo, Pharmstandard PJSC purchase Biocad Holding Ltd.

Clients

Oxford Immunotec Global Plc operates as a diagnostics company, which develops and commercializes proprietary tests for immunology and infectious disease. Its products include T-SPOT.TB, T-SPOT.CMV, T-SPOT.PRT and T-CELL XTEND. The company was founded by Peter James Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom.

OTCPharm PJSC engages in the production, marketing, promotion and wholesaling of pharmaceutical products. Its product portfolio brands include Arbidol, Pentalgin, Complivit, Flucostat, Aphobasolum, Codelac, Amixin, Acipol, Maxicold, Rinostop, Magnelis B6, Noopept, Asvitol, Ascophen-P, Next, Lactazar, Selmevit, Termicon, Lactonorm, Cyclovita, Cynocap, Univit, Nitrocor, Neosmectin, Klarisens, Azitrox, Gastrozol, Mycoderil. The company was founded on December 23, 2013 and is headquartered in Moscow, Russia.

Key Stats and Financials As of
Market Capitalization
$39.2B
Total Enterprise Value
Earnings Per Share
Investments
Details Hidden

Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA.

Details Hidden

Argos Therapeutics, Inc. is a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and is headquartered in Durham, NC.

Suppliers
Chiesi Farmaceutici SpA Retail: Drug Stores | Parma, Italy

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Argos Therapeutics, Inc. Pension Funds & Sovereign Wealth | Durham, North Carolina

Argos Therapeutics, Inc. is a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and is headquartered in Durham, NC.

Les Laboratoires Servier SAS Pharmaceuticals | Suresnes, France

Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Pharmstandard PJSC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Pharmstandard PJSC's profile does not indicate a business or promotional relationship of any kind between RelSci and Pharmstandard PJSC.